Newsroom | 4702 results

FRAMINGHAM, Mass.--(BUSINESS WIRE)--TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, is available to customers at Publix Super Markets (Publix) pharmacies. Publix, the largest employee-owned company in the country, has over 1,400 locations throughout the Southeast United States. “TheracosBio is committed to increasing access to effective, low-cost medications,” said Brian Conn...

DOYLESTOWN, Pa.--(BUSINESS WIRE)--Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects...

NEW YORK--(BUSINESS WIRE)--Levels, the health technology company known for pioneering real-time glucose insights for health-conscious consumers, today introduced its most robust offering yet: adding comprehensive blood testing, dietitian support, and AI-powered guidance. Levels now covers a broad range of health markers and interventions. The updated offering includes an essential 28-marker blood panel or a 100+ marker panel, access to insurance-covered 1-1 Registered Dietitian Nutritionists (R...

ST. LOUIS PARK, Minn.--(BUSINESS WIRE)--Enterra Medical, Inc., a leader in innovative treatments for gastrointestinal disorders, has initiated the NAVIGATE study to evaluate the safety and effectiveness of Gastric Electrical Stimulation (GES) as a treatment for patients with chronic nausea that have normal gastric emptying. This study was approved as an IDE study by the U.S. Food and Drug Administration (FDA) and was subsequently granted Breakthrough Device designation. NAVIGATE and its potenti...

LOS ANGELES--(BUSINESS WIRE)--City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named a Top 5 “Best Hospital” in the nation for cancer care by U.S. News & World Report, is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials and empower breakthrough research. “With the rise of AI, health care sys...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented data from the randomized, double-blind, placebo-controlled treatment phase of its CATALYST trial of Korlym® in patients with hypercortisolism (Cushing’s syndrome) and difficult-to-co...

LOS ANGELES--(BUSINESS WIRE)--Scientists with City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, and a leading research center for diabetes and other life-threatening illnesses, presented their latest research findings at the American Diabetes Association’s 85th Scientific Sessions, June 20-23, 2025, at the McCormick Place Convention Center in Chicago. “City of Hope studies featured at this year’s ADA meeting offer remarkable ne...

LOS ANGELES--(BUSINESS WIRE)--Laekna (2105.HK) announced today that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA). ADA is one of the global lea...

IRVING, Texas--(BUSINESS WIRE)--Vizient company Sg2 announced the 2025 Impact of Change® Forecast, highlighting 18% growth in adult outpatient volumes over the next decade....

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase 3 clinical studies designed to support regulatory submissions for marketing approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned su...